Table 1.

Correlation between RON and MET expression and clinical characteristics of patients with triple-negative breast cancer

Factor	Total, n (%)	RON			MET			RON and MET co-expression
		Low	High	p-value	Low	High	p-value	Low	High	p-value
Age
Mean±SD	52.82±12.44	51.77	54.89	0.165	52.27	53.92	0.413	52.03	55.47	0.113
Lymph node metastasis
Yes	48 (25.7)	28	20	0.175	33	15	0.678	37	11	0.999
None	139 (74.3)	96	43		91	48		107	32
Distant metastasis
Yes	19 (10.2)	11	8	0.413	11	8	0.413	13	6	0.348
None	168 (89.8)	113	55		113	55		131	37
TNM stage
Stage I	85 (45.5)	58	27	0.212	58	27	0.750	65	20	0.982
Stage II	85 (45.5)	58	27		56	29		66	19
Stage III	17 (9.1)	8	9		10	7		13	4
Differentiation
Well	1 (0.5)	0	1	0.488	0	1	0.341	0	1	0.326
Moderate	20 (10.7)	12	8		11	9		15	5
Poor	147 (78.6)	99	48		100	47		114	33
Unknown	19 (10.2)	13	6		13	6		15	4
Treatment
Chemotherapy	161 (86.1)	108	53	0.539	106	55	0.735	126	35	0.310
None	26 (13.9)	16	10		18	8		18	8
Surgical procedures
Conserving surgery	29 (15.5)	21	8	0.656	22	7	0.496	24	5	0.427
Simple mastectomy	76 (40.6)	48	28		49	27		55	21
Radical mastectomy	82 (43.9)	55	27		53	29		65	17
Tumor size (cm3)
≥ 5	88 (47.1)	57	31	0.675	54	34	0.177	66	22	0.539
< 5	99 (52.9)	67	32		70	29		78	21